Posts

Showing posts from 2017

Announcing the "Portable Expiratory CO Concentration Measuring Device Integrated Therapeutic Application" IoT Device.

Image
We have developed the "Portable Expiratory CO Concentration Measuring Device Integrated Therapeutic Application" IoT Device to allow for the measurement of exhaled carbon monoxide (CO) concentrations in smoking cessation treatments in the field of telemedicine. In recent years, the government's Future Investment Conference and the Ministry of Health, Labor and Welfare have been discussing about the expansion of insurance applications to telemedicine. Smoking cessation therapy has become a hot topic. One of the challenges have been that one of the main conditions for the current insurance application, the measurement of the carbon monoxide (CO) concentration in breath, cannot be performed remotely. Patients must attend a medical facility to obtain these results. We are proud to announce that CureApp Inc. (Headquarters: Chuo-ku, Tokyo, President and CEO: Kota Satake) offers a "portable IoT device" that enables patients to measure breath CO concentrat

CureApp, Inc. Launches the "ascure smoking cessation program" as the first step of its corporate "mobile health program".

Image
The CureApp, Inc. Corporate "Mobile Health Program". The first step began with the ascure (ascure) smoking cessation program aiming to improve smoking cessation success rates with a "complete online 6 month support" application with non-smoking instructors. The disease treatment program, CureApp Co., Ltd. (headquartered in Chuo-ku, Tokyo; President: Kota Satake), deals with the research and development to the manufacturing and sale of "therapeutic applications". We are pleased to announce that we have begun offering the "ascure smoking cessation program" as the first step in our health promotion program for corporate users. In recent years, increased efforts to promote health awareness in companies and health insurance agencies have become an issue due to the soaring medical costs that occur when employees fall ill and the associated effects to employee productivity etc. Health management centered on the Ministry of Economy, Trade and Indu

CureApp, Inc. implemented a third party allotment of new shares totaling 380 million JPY

Image
CureApp, Inc. (headquartered in Chuo-ku, Tokyo: President and CEO: Kota Satake) which is engaged in the research and development of therapeutic applications as medical devices as well as their manufacture and sale, has today announced that Beyond Next Ventures and Keio Innovation has implemented a third party allotment capital of 380 million JYN taken on by SBI Investments. [Overview of Underwrite] Beyond Next Ventures Head Office: 1-4-3 Nihonbashi Honcho, Chuo-ku, Tokyo Representative Director and President: Takeshi Ito Keio Innovation Initiative Headquarters: Mita 1-4-28, Minato-ku, Tokyo Representative Director: Hirotaro Yamagishi SBI Investment Head office: 1-6-1 Roppongi, Minato-ku, Tokyo Representative Director and Executive Officer President: Katsuya Kawashima [Implementation Background and Objectives] CureApp aims to create individually optimized (personalized) medical care that achieves a superb therapeutic effect as a form of new medical treatment